Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 1
2021 2
2022 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Results by year

Filters applied: . Clear all
Page 1
Ipilimumab in a real-world population: A prospective Phase IV trial with long-term follow-up.
Aamdal E, Jacobsen KD, Straume O, Kersten C, Herlofsen O, Karlsen J, Hussain I, Amundsen A, Dalhaug A, Nyakas M, Schuster C, Hagene KT, Holmsen K, Russnes HG, Skovlund E, Kaasa S, Aamdal S, Kyte JA, Guren TK. Aamdal E, et al. Int J Cancer. 2022 Jan 1;150(1):100-111. doi: 10.1002/ijc.33768. Epub 2021 Sep 9. Int J Cancer. 2022. PMID: 34449877 Free article. Clinical Trial.
Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma.
Nyakas M, Aamdal E, Jacobsen KD, Guren TK, Aamdal S, Hagene KT, Brunsvig P, Yndestad A, Halvorsen B, Tasken KA, Aukrust P, Maelandsmo GM, Ueland T. Nyakas M, et al. Among authors: aamdal e. Clin Exp Immunol. 2019 Jul;197(1):74-82. doi: 10.1111/cei.13283. Epub 2019 Mar 21. Clin Exp Immunol. 2019. PMID: 30821848 Free PMC article. Clinical Trial.
Health-related quality of life in patients with advanced melanoma treated with ipilimumab: prognostic implications and changes during treatment.
Aamdal E, Skovlund E, Jacobsen KD, Straume O, Kersten C, Herlofsen O, Karlsen J, Hussain I, Amundsen A, Dalhaug A, Nyakas M, Hagene KT, Holmsen K, Aamdal S, Kaasa S, Guren TK, Kyte JA. Aamdal E, et al. ESMO Open. 2022 Oct;7(5):100588. doi: 10.1016/j.esmoop.2022.100588. Epub 2022 Sep 16. ESMO Open. 2022. PMID: 36116420 Free PMC article.
Characterization of the T cell receptor repertoire and melanoma tumor microenvironment upon combined treatment with ipilimumab and hTERT vaccination.
Ellingsen EB, Bounova G, Kerzeli I, Anzar I, Simnica D, Aamdal E, Guren T, Clancy T, Mezheyeuski A, Inderberg EM, Mangsbo SM, Binder M, Hovig E, Gaudernack G. Ellingsen EB, et al. Among authors: aamdal e. J Transl Med. 2022 Sep 11;20(1):419. doi: 10.1186/s12967-022-03624-z. J Transl Med. 2022. PMID: 36089578 Free PMC article. Clinical Trial.
Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials.
Ellingsen EB, Aamdal E, Guren T, Lilleby W, Brunsvig PF, Mangsbo SM, Aamdal S, Hovig E, Mensali N, Gaudernack G, Inderberg EM. Ellingsen EB, et al. Among authors: aamdal e. J Immunother Cancer. 2022 May;10(5):e004345. doi: 10.1136/jitc-2021-004345. J Immunother Cancer. 2022. PMID: 35613827 Free PMC article.
Combining a Universal Telomerase Based Cancer Vaccine With Ipilimumab in Patients With Metastatic Melanoma - Five-Year Follow Up of a Phase I/IIa Trial.
Aamdal E, Inderberg EM, Ellingsen EB, Rasch W, Brunsvig PF, Aamdal S, Heintz KM, Vodák D, Nakken S, Hovig E, Nyakas M, Guren TK, Gaudernack G. Aamdal E, et al. Front Immunol. 2021 May 11;12:663865. doi: 10.3389/fimmu.2021.663865. eCollection 2021. Front Immunol. 2021. PMID: 34046035 Free PMC article. Clinical Trial.